Skip to content
Review

Lipid-based nanocarrier-enabled combination therapy for breast cancer: overcoming drug resistance toward precision oncology.

Jul 2026 · Naunyn-Schmiedeberg's Archives of Pharmacology · 0 citations · 170 references
Medicine

TL;DR

This paper presents a comprehensive review of recent advances in lipid-based nanocarrier-mediated combination therapies in breast cancer treatment, highlighting the need for developing more effective and specific strategies to address the mentioned obstacles.

View source

Similar papers

Review Aug 2026

Protein Nanomedicine in Breast Cancer Therapy: Targeting Strategies, Clinical Applications, and Future Perspectives

The present review examines the possibilities of using protein-based nanomedicine in breast cancer treatment by looking at targeted drug delivery, immune modulation, and the mechanism of enhanced permeability and retention (EPR) for the precise targeting of the tumour.

S. H. Almurisi, Chua-Hsuan Kai, Foo Yoong Kit et al. · 0 citations
Review Open access Sep 2026

Natural Product-Based Nanomedicine in the Treatment of Breast Cancer

This review evaluates diverse nanoparticle-based delivery systems and their targeting mechanisms in natural product-based breast cancer therapy and concludes that natural products possess potent anti-breast cancer effects, and the application of nanodelivery technology effectively overcomes their inherent limitations o...

Kai-Yan Su, Yan Li, Dong-Mei Zhang et al. · 0 citations
Review Open access Aug 2026

Nanomedicine strategies for overcoming multidrug resistance in breast cancer: recent advances and future perspectives

Overall, nanomedicine offers a multifaceted and promising approach to overcome MDR in breast cancer; however, further translational and clinical studies are required to fully realize its therapeutic potential.

Mohit Kumar, Tejaswi, Rohit Bangwal et al. · 0 citations
Review Open access Aug 2026

Nano-enabled delivery of natural products and combinatorial chemotherapy for triple-negative breast cancers: mechanisms, synergy, and translational challenges

This review critically evaluates current methodologies for assessing drug synergism, including the Chou–Talalay, Bliss independence, and Loewe additivity models, and highlights the lack of standardized application across studies, as well as addressing key translational challenges.

Somaia T Mansour, Wael Mamdouh · 0 citations
Review Open access Jul 2026

Antibody-drug conjugates in the treatment of breast cancer

Overall, the results suggest that despite the challenges, this technology represents a significant advance in breast cancer therapy and that the integration of combined and personalized strategies may enhance antibody efficacy, overcome current barriers and contribute to better clinical outcomes.

A. D. da Cruz, M. Lima, Bárbara Sentanin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.